JETABLE launches “JET-LAG-SPRAY” for effective travel fatigue


DISPOSABLE INTERNATIONAL, INC., today announced the official launch of a new anti-fatigue drug remedy called; JET-LAG-SPRAY. In the future, airline flight crews and frequent flyers could improve their mental and physical acuity by using an oral potassium electrolyte anti-fatigue spray. The results of a prospective clinical study suggest that JET-LAG-SPRAY can be used as a safe and effective alternative to conventional Airport Kiosk homeopathic formulations such as “No-Jet-Lag” or “JetLagFX” used to stay focused and alert during long-haul international flights. JET-LAG-SPRAY helps boost natural immunity, protecting against harmful radioactive iodine, colds and flu virus.

JET-LAG-SPRAY is a special blend of potassium iodide and bioactive compounds designed to help naturally support the immune system. Air travel across multiple time zones produces jet lag, which includes difficulty initiating or maintaining nocturnal sleep, daytime sleepiness, decreased alertness, loss of concentration, impaired performance, fatigue , irritability, disorientation, depressed mood and gastrointestinal disturbances. Jet lag poses a threat to public safety as it affects civilian and military pilots.

“With Airport Kiosk product placement, we are able to increase last-minute impulse purchases of JET-LAG-SPRAY, purchased by frequent flyers about to board long-haul international flights,” said said Richard H, DAVIS, Chairman and CEO of DISPOSABLE INTERNATIONAL, INC. “No one ever plans ahead for jet lag prevention, air travelers just buy the product when they see it,” DAVIS said.

† These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

To learn more, visit:

Richard H, DAVIS
Chairman and CEO
Tel: +33 7 5713 0799 | [email protected]

DISPOSABLE INTERNATIONAL, INC., is a leading biotechnology company focused on the discovery, development and commercialization of novel biomedical technologies to address cognitive issues in neurodegenerative diseases and other aspects of aging and related memory loss. at the age.

This press release was published on openPR.

Comments are closed.